Evidence map›Paper›PMID 22140072›Full record

ArticleAmerican journal of physiology. Lung cellular and molecular physiology2012

Regulation of alveolar epithelial cell apoptosis and pulmonary fibrosis by coordinate expression of components of the fibrinolytic system.

Yashodhar P Bhandary, Shwetha K Shetty, Amarnath S Marudamuthu, Margaret R Gyetko, Steven Idell, Mehrnaz Gharaee-Kermani, Rashmi S Shetty, Barry C Starcher, Sreerama Shetty

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Lung cellular and molecular physiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 78 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. p53-miR-34a feedback in lung fibroblasts regulates antifibrotic effects of CSP7, nintedanib, and pirfenidone.American journal of physiology. Lung cellular and molecular physiology · 2025
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yashodhar P BhandaryTexas Lung Injury Institute, Department of Medicine, The University of Texas Health Science Center, Tyler, Texas 75708, USA.
Shwetha K Shetty
Amarnath S Marudamuthu
Margaret R Gyetko
Steven Idell
Mehrnaz Gharaee-Kermani
Rashmi S Shetty
Barry C Starcher
Sreerama Shetty
University of Michigan · USThe University of Texas Health Science Center at Tyler · US

Funding

Regulation of lung epithelial injury by plasminogen activator inhibitor-1R21HL093547 · NHLBI · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI SHETTY, SREERAMA · 2010 to 2011
$388k
NHLBI NIH HHS R21-HL093547
6 · The paper itself

Abstract

Alveolar type II (ATII) cell apoptosis and depressed fibrinolysis that promotes alveolar fibrin deposition are associated with acute lung injury (ALI) and the development of pulmonary fibrosis (PF). We therefore sought to determine whether p53-mediated inhibition of urokinase-type plasminogen activator (uPA) and induction of plasminogen activator inhibitor-1 (PAI-1) contribute to ATII cell apoptosis that precedes the development of PF. We also sought to determine whether caveolin-1 scaffolding domain peptide (CSP) reverses these changes to protect against ALI and PF. Tissues as well as isolated ATII cells from the lungs of wild-type (WT) mice with BLM injury show increased apoptosis, p53, and PAI-1, and reciprocal suppression of uPA and uPA receptor (uPAR) protein expression. Treatment of WT mice with CSP reverses these effects and protects ATII cells against bleomycin (BLM)-induced apoptosis whereas CSP fails to attenuate ATII cell apoptosis or decrease p53 or PAI-1 in uPA-deficient mice. These mice demonstrate more severe PF. Thus p53 is increased and inhibits expression of uPA and uPAR while increasing PAI-1, changes that promote ATII cell apoptosis in mice with BLM-induced ALI. We show that CSP, an intervention targeting this pathway, protects the lung epithelium from apoptosis and prevents PF in BLM-induced lung injury via uPA-mediated inhibition of p53 and PAI-1.

Indexed as

Gene ExpressionAcute Lung InjuryAnimalsApoptosisBleomycinCaveolin 1Cells, CulturedCollagenCytoprotectionHumansLungMiceMice, Inbred C57BLMice, TransgenicPeptide FragmentsPlasminogen Activator Inhibitor 1BleomycinCaveolin 1caveolin-1 (82-101)CollagenParp1 protein, mousePeptide FragmentsPlasminogen Activator Inhibitor 1Poly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) PolymerasesReceptors, Urokinase Plasminogen ActivatorSERPINE1 protein, humanTP53 protein, humanTumor Suppressor Protein p53Urokinase-Type Plasminogen Activator

Identifiers

PMID22140072
PMCPMC3311514
OpenAlexW2127612422

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.